QuantuMDx - Changing healthcare, Globally

QuantuMDx Group Logo
Q-POC™
Tackling humanitarian
health priorities
Malaria, TB & HIV diagnosis and drug resistance status for a few dollars
Q-POC™
The Handheld Laboratory
15 minute disease diagnosis at the
touch of a button
Q-POC™
Personalising Medicine
Right first time prescribing for your patients
Q-POC™
Digitizing Biology
Translating DNA the code of life into binary code
Q-POC™
One Device,
Endless Possibilities
Flexibility to extract and analyse DNA from most sample types
Our Commercial testing laboratory
One Device, Endless Possibilities™
Q-POC™: The Handheld Laboratory

Q-POC™ - analysing DNA in under 15 minutes.
The smartphone-like device will provide the accuracy, sensitivity and specificity of a state of the art laboratory, at the patient's side and at a fraction of the cost.

Q-POC™

Disease diagnosis in under 15 minutes

Q-POC™ is a dynamic platform capable of analysing DNA in under 15 minutes. The smartphone-like device will provide the accuracy, sensitivity and specificity of a state of the art laboratory, at the patient's side and at a fraction of the cost. Disposable test-specific cartridges for infectious diseases, cancer and pharmacogenetics are in development with our partners.

Benefiting patients, globally Q-POC™ will

  • Enable healthcare workers to prescribe the right drug at the right dose first time
  • Use easy-to-obtain samples such as a fingerprick of blood
  • Eliminate the need for repeat doctors' visits and reduce patient anxiety
  • Provide rapid testing to patients in busy urban hospitals
  • Deliver accurate diagnostic testing to remote underserved communities
  • Offer the opportunity for convenient diagnostic testing at home for isolated patients, such as the elderly and disabled

Empowering healthcare workers, globally Q-POC™ will

  • Put the power of a full diagnostics laboratory into the palm of healthcare workers hands
  • Simplify complex DNA analysis
  • Tailor results readout to suit the users' needs, whether they require a yes/no diagnostic result or a full laboratory report
  • Streamline workflows by providing results in 10-15 minutes
  • Employ an intuitive touchscreen display
  • Integrate with healthcare infrastructure and cloud-based databases with smartphone connectivity

Q-POC™ integrates QuantuMDx's novel Q-prep™, Q-amp™ and Q-detect™ technologies into an easy to use handheld device. The DNA extraction, amplification and detection processes all occur along one microfluidic channel, making the fluidics simple, robust and reproducible. Modelling has shown that the integration of these technologies will produce a handheld device that is not only low cost and low weight, but has a low energy consumption.

Q-POC™ - analysing DNA in under 15 minutes.

The smartphone-like device will provide the accuracy, sensitivity and specificity of a state of the art laboratory, at the patient's side and at a fraction of the cost.

QuantuMDx are developing an automated DNA extraction device

Malaria hits rural dwellers in poor countries the hardest. Those bitten by the wrong mosquito often do not know for many days that they have contracted malaria. Some have little or no access to doctors. There are times when, even if the tests confirm the disease soon enough, standard treatments may not help because they may be suffering from the drug-resistant strain of the parasite.

QuantuMDx and Genome Institute of Singapore announce collaboration

A*STAR's Genome Institute of Singapore (GIS) has signed an agreement with QuantuMDx (QMDx), a UK-based biotech developing handheld diagnostics and whole genome sequencing devices. Under this collaboration, QMDx's wholly owned Singapore-based subsidiary QMDx Asia and GIS will develop Asia-specific point-of-care genetic tests for use with Q-POC™, QMDx's handheld point-of-care device. QMDx will commercialize the tests. The first assay from the development pipeline will direct treatment of East Asian patients with kinase-driven cancers, such as chronic myeloid leukemia (CML) and epidermal growth factor receptor-mutated non-small lung cancer (EGFR NSCLC).

Nanomal present handheld device at BioMalPar

Today Nanomal lead Professor Sanjeev Krishna of St George's, University of London will be presenting the consortium's ground-breaking handheld device for rapid detection of malaria infection and drug resistance at the 9 th Annual BioMalPar conference. The conference is sponsored by the European Virtual Institute of Malaria Research (EVIMalaR), Europe's largest malaria research institute with partners across Europe, Africa and India. Both EVIMalaR and the €5.2 million Nanomal project are EU-funded FP7 projects.

 
QuantuMDx DevicesQuantuMDx MissionQuanutMDx ProductsQuantuMDx DevicesQuantuMDx developing new assays